Sophia M. Guldberg

Sophia M. Guldberg

Auto-generated profile, based on publicly available information

Sophia M. Guldberg

University of California San Francisco 2 Biomedical Sciences Graduate Program San Francisco, California

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 December 2019 in Toxins
Verified
Journal Article
Open access
PDF file
RWRebekah Wharton
Rebekah Wharton
BCBrady Cunningham
Brady Cunningham
ASAdam Schaefer
Adam Schaefer
SGSophia M. Guldberg
Sophia M. Guldberg
EHElizabeth I Hamelin
Elizabeth I Hamelin
RJRudolph C. Johnson
Rudolph C. Johnson
Microcystins (MC) and nodularin (NOD) are toxins released by cyanobacteria during harmful algal blooms. They are potent inhibitors of protein phosphatases 1 and 2A (PP1 and PP2A) and cause a variety of adverse symptoms in humans and animals if ingested. More than 250 chemically diverse congeners of MCs have been identified, but certified reference materials are only available for a few. A diagnostic test that does not require each reference material for detection is necessary to identify human exposures. To address this need, our lab has developed a method that uses an antibody to specifically isolate MCs and NOD from urine prior to detection via a commercially available PP2A kit. This assay quantitates the summed inhibitory activity of nearly all MCs and NOD on PP2A relative to a common MC congener, microcystin-LR (MC-LR). The quantitation range for MC-LR using this method is from 0.050–0.500 ng/mL. No background responses were detected in a convenience set of 50 individual urines. Interday and intraday % accuracies ranged from 94%–118% and relative standard deviations were 15% or less, meeting FDA guidelines for receptor binding assays. The assay detected low levels of MCs in urines from three individuals living in close proximity to harmful algal blooms (HABs) in Florida.

10 December 2018 in ACS Applied Bio Materials
Verified
Journal Article
Closed access
SCStephen Crooke
Stephen Crooke
JZJukuan Zheng
Jukuan Zheng
MGMitra S. Ganewatta
Mitra S. Ganewatta
SGSophia M. Guldberg
Sophia M. Guldberg
TRTheresa M. Reineke
Theresa M. Reineke
MFM.G. Finn
M.G. Finn

15 October 2024 in Cancer Immunology Research
Verified
Journal Article
Closed access
PDF file
NCNam Woo Cho
Nam Woo Cho
SGSophia M. Guldberg
Sophia M. Guldberg
BNBarzin Y. Nabet
Barzin Y. Nabet
JYJie Zeng Yu
Jie Zeng Yu
EKEun Ji Kim
Eun Ji Kim
MSMatthew H. Spitzer
Matthew H. Spitzer
Resistance to immune checkpoint inhibitors (ICI) is common, even in tumors with T-cell infiltration. We thus investigated consequences of ICI-induced T-cell infiltration in the microenvironment of resistant tumors. T cells and neutrophil numbers increased in ICI-resistant tumors following treatment, in contrast to ICI-responsive tumors. Resistant tumors were distinguished by high expression of IL1 receptor 1, enabling a synergistic response to IL1 and TNFα to induce G-CSF, CXCL1, and CXCL2 via NF-κB signaling, supporting immunosuppressive neutrophil accumulation in tumor. Perturbation of this inflammatory resistance circuit sensitized tumors to ICIs. Paradoxically, T cells drove this resistance circuit via TNFα both in vitro and in vivo. Evidence of this inflammatory resistance circuit and its impact also translated to human cancers. These data support a mechanism of ICI resistance, wherein treatment-induced T-cell activity can drive resistance in tumors responsive to IL1 and TNFα, with important therapeutic implications.

10 October 2025 in Science Advances
Verified
Journal Article
Open access
BKBridget P. Keenan
Bridget P. Keenan
GQGuilin Qiao
Guilin Qiao
NKNicholas Kunda
Nicholas Kunda
LKLyonell Kone
Lyonell Kone
SGSophia M. Guldberg
Sophia M. Guldberg
AMAjay V. Maker
Ajay V. Maker
Colorectal cancer and liver metastases are a leading cause of cancer-related mortality. Overexpression of the immunostimulatory cytokine TNFSF14/LIGHT associates with improved survival and correlates with increased tumor-infiltrating lymphocytes in patients and a clinically relevant model of colorectal liver metastases. We demonstrate that LIGHT monotherapy activates T cells, but also induces T cell exhaustion and the recruitment of immunosuppressive elements. As colorectal liver metastases exhibit high levels of CTLA-4 expression, we combined LIGHT overexpression with anti-CTLA-4, leading to complete tumor control. The combination functions by homing tumor-infiltrating lymphocytes, inducing tumor antigen-specific T cells, and reversing T cell exhaustion. Whereas both LIGHT overexpression and anti-CTLA-4 increase tumor-promoting macrophages, the combination eliminates this population. The ability of LIGHT overexpression combined with CTLA-4 inhibition to reverse T cell exhaustion and myeloid cell suppression is supported by analysis of complementary patient cohorts and has strong clinical relevance, especially given that liver metastases contribute to immunotherapy resistance across various cancer types.

3 February 2025
Verified
Other
Open access
NCNam Woo Cho
Nam Woo Cho
SGSophia M. Guldberg
Sophia M. Guldberg
BNBarzin Y. Nabet
Barzin Y. Nabet
JYJie Zeng Yu
Jie Zeng Yu
EKEun Ji Kim
Eun Ji Kim
MSMatthew H. Spitzer
Matthew H. Spitzer
Resistance to immune checkpoint inhibitors (ICI) is common, even in tumors with T-cell infiltration. We thus investigated consequences of ICI-induced T-cell infiltration in the microenvironment of resistant tumors. T cells and neutrophil numbers increased in ICI-resistant tumors following treatment, in contrast to ICI-responsive tumors. Resistant tumors were distinguished by high expression of IL1 receptor 1, enabling a synergistic response to IL1 and TNFα to induce G-CSF, CXCL1, and CXCL2 via NF-κB signaling, supporting immunosuppressive neutrophil accumulation in tumor. Perturbation of this inflammatory resistance circuit sensitized tumors to ICIs. Paradoxically, T cells drove this resistance circuit via TNFα both in vitro and in vivo. Evidence of this inflammatory resistance circuit and its impact also translated to human cancers. These data support a mechanism of ICI resistance, wherein treatment-induced T-cell activity can drive resistance in tumors responsive to IL1 and TNFα, with important therapeutic implications.